{"id":50968,"date":"2025-12-16T21:58:29","date_gmt":"2025-12-16T13:58:29","guid":{"rendered":"https:\/\/flcube.com\/?p=50968"},"modified":"2025-12-16T21:58:30","modified_gmt":"2025-12-16T13:58:30","slug":"dren-bio-sanofi-forge-1-8b-b-cell-therapy-deal-with-us-co-promote-option","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50968","title":{"rendered":"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option"},"content":{"rendered":"\n<p><strong>Dren Bio, Inc.<\/strong> announced a strategic collaboration with <strong>Sanofi<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NASDAQ: SNY<\/a>) to discover and develop a next\u2011generation <strong>B\u2011cell depleting therapy<\/strong> for autoimmune diseases. The agreement builds on Sanofi\u2019s earlier 2025 acquisition of Dren\u2019s <strong>DR\u20110201 program<\/strong> (now SAR448501) and includes a <strong>$100\u202fmillion upfront payment<\/strong> plus up to <strong>$1.7\u202fbillion in milestones<\/strong>. Dren retains an option to <strong>co\u2011fund 40% of US development costs<\/strong> for <strong>50\/50 profit\/loss sharing<\/strong> and co\u2011promotion rights.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 100\u202fmillion<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD 1.7\u202fbillion (development, regulatory, commercial)<\/td><\/tr><tr><td><strong>Collaboration Scope<\/strong><\/td><td>Discovery and preclinical development of next\u2011gen B\u2011cell depleter<\/td><\/tr><tr><td><strong>Post\u2011Candidate Responsibility<\/strong><\/td><td>Sanofi assumes development, manufacturing, regulatory, and commercialization<\/td><\/tr><tr><td><strong>US Option<\/strong><\/td><td>Dren Bio may elect 40% cost share for 50\/50 US profit\/loss share and co\u2011promotion<\/td><\/tr><tr><td><strong>Ex\u2011US Economics<\/strong><\/td><td>Dren eligible for milestones and tiered royalties on net sales outside US<\/td><\/tr><tr><td><strong>Existing Asset<\/strong><\/td><td>DR\u20110201 (SAR448501) in Phase\u202f1, showing robust B\u2011cell depletion and potential for treatment\u2011free remission<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>DR\u20110201\/SAR448501:<\/strong> Acquired by Sanofi earlier in 2025; two ongoing Phase\u202f1 studies in autoimmune diseases; demonstrates <strong>deep B\u2011cell depletion<\/strong> with potential for <strong>sustained remission<\/strong>.<\/li>\n\n\n\n<li><strong>Platform:<\/strong> Dren\u2019s proprietary B\u2011cell targeting platform enables discovery of <strong>novel depleting agents<\/strong> with improved selectivity and safety profiles.<\/li>\n\n\n\n<li><strong>Market:<\/strong> Global autoimmune B\u2011cell depletion market exceeds <strong>$12\u202fbillion<\/strong> (2025), dominated by rituximab biosimilars and newer agents; next\u2011gen therapies aim to reduce infusion reactions and improve durability.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Dren Bio:<\/strong> <strong>$1.8\u202fbillion deal value<\/strong> validates platform beyond initial asset monetization; <strong>US co\u2011promote option<\/strong> provides <strong>retained upside<\/strong> in largest market; non\u2011dilutive funding accelerates platform expansion.<\/li>\n\n\n\n<li><strong>For Sanofi:<\/strong> Secures <strong>first\u2011class B\u2011cell platform<\/strong> to complement SAR448501; addresses <strong>autoimmune pipeline gap<\/strong> after Kevzara and Dupixent; positions for <strong>leadership in B\u2011cell mediated diseases<\/strong> (SLE, RA, MG).<\/li>\n\n\n\n<li><strong>For Market:<\/strong> Demonstrates <strong>pharma appetite<\/strong> for next\u2011generation depleting technologies; <strong>Dren\u2019s platform<\/strong> could generate <strong>multiple IND candidates<\/strong> beyond the initial collaboration; sets precedent for <strong>flexible deal structures<\/strong> with biotech retain options.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievements, clinical development timelines, and the execution of the US co\u2011promote option. Actual results may differ due to scientific risks, competitive responses, or regulatory challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50969,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[476,867,147],"class_list":["post-50968","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-dren-bio","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop a next\u2011generation B\u2011cell depleting therapy for autoimmune diseases. The agreement builds on Sanofi\u2019s earlier 2025 acquisition of Dren\u2019s DR\u20110201 program (now SAR448501) and includes a $100\u202fmillion upfront payment plus up to $1.7\u202fbillion in milestones. Dren retains an option to co\u2011fund 40% of US development costs for 50\/50 profit\/loss sharing and co\u2011promotion rights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50968\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option\" \/>\n<meta property=\"og:description\" content=\"Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop a next\u2011generation B\u2011cell depleting therapy for autoimmune diseases. The agreement builds on Sanofi\u2019s earlier 2025 acquisition of Dren\u2019s DR\u20110201 program (now SAR448501) and includes a $100\u202fmillion upfront payment plus up to $1.7\u202fbillion in milestones. Dren retains an option to co\u2011fund 40% of US development costs for 50\/50 profit\/loss sharing and co\u2011promotion rights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50968\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-16T13:58:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-16T13:58:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option\",\"datePublished\":\"2025-12-16T13:58:29+00:00\",\"dateModified\":\"2025-12-16T13:58:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1602.webp\",\"keywords\":[\"Dren Bio\",\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50968#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50968\",\"name\":\"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1602.webp\",\"datePublished\":\"2025-12-16T13:58:29+00:00\",\"dateModified\":\"2025-12-16T13:58:30+00:00\",\"description\":\"Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop a next\u2011generation B\u2011cell depleting therapy for autoimmune diseases. The agreement builds on Sanofi\u2019s earlier 2025 acquisition of Dren\u2019s DR\u20110201 program (now SAR448501) and includes a $100\u202fmillion upfront payment plus up to $1.7\u202fbillion in milestones. Dren retains an option to co\u2011fund 40% of US development costs for 50\\\/50 profit\\\/loss sharing and co\u2011promotion rights.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50968\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50968#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option - Insight, China&#039;s Pharmaceutical Industry","description":"Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop a next\u2011generation B\u2011cell depleting therapy for autoimmune diseases. The agreement builds on Sanofi\u2019s earlier 2025 acquisition of Dren\u2019s DR\u20110201 program (now SAR448501) and includes a $100\u202fmillion upfront payment plus up to $1.7\u202fbillion in milestones. Dren retains an option to co\u2011fund 40% of US development costs for 50\/50 profit\/loss sharing and co\u2011promotion rights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50968","og_locale":"en_US","og_type":"article","og_title":"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option","og_description":"Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop a next\u2011generation B\u2011cell depleting therapy for autoimmune diseases. The agreement builds on Sanofi\u2019s earlier 2025 acquisition of Dren\u2019s DR\u20110201 program (now SAR448501) and includes a $100\u202fmillion upfront payment plus up to $1.7\u202fbillion in milestones. Dren retains an option to co\u2011fund 40% of US development costs for 50\/50 profit\/loss sharing and co\u2011promotion rights.","og_url":"https:\/\/flcube.com\/?p=50968","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-16T13:58:29+00:00","article_modified_time":"2025-12-16T13:58:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50968#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50968"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option","datePublished":"2025-12-16T13:58:29+00:00","dateModified":"2025-12-16T13:58:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50968"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50968#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1602.webp","keywords":["Dren Bio","NASDAQ: SNY","Sanofi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50968#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50968","url":"https:\/\/flcube.com\/?p=50968","name":"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50968#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50968#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1602.webp","datePublished":"2025-12-16T13:58:29+00:00","dateModified":"2025-12-16T13:58:30+00:00","description":"Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop a next\u2011generation B\u2011cell depleting therapy for autoimmune diseases. The agreement builds on Sanofi\u2019s earlier 2025 acquisition of Dren\u2019s DR\u20110201 program (now SAR448501) and includes a $100\u202fmillion upfront payment plus up to $1.7\u202fbillion in milestones. Dren retains an option to co\u2011fund 40% of US development costs for 50\/50 profit\/loss sharing and co\u2011promotion rights.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50968#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50968"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50968#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1602.webp","width":1080,"height":608,"caption":"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50968#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dren Bio, Sanofi Forge $1.8B B\u2011Cell Therapy Deal with US Co\u2011Promote Option"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50968"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50968\/revisions"}],"predecessor-version":[{"id":50970,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50968\/revisions\/50970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50969"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}